Jubilant Life Sciences surges over 4% after getting approval for remdesivir in India for treating Covid-19

The companys subsidiary, Jubilant Generics Limited has got nod from DCGI to manufacture and market the investigational antiviral drug remdesivir (JUBI-R).

from India Infoline News Service https://ift.tt/2OLVGnG